Febubow 40 Tablet 10: Uses, Side Effects, Price & Substitutes

About Febubow-40 Tablet

Febubow-40 Tablet is a medicine used to manage gout, a condition that causes painful and swollen joints due to the buildup of uric acid in the body. Gout usually affects one joint, causing sudden and severe pain, redness, warmth, and swelling. The medicine helps reduce uric acid levels, preventing gout attacks.

To take this medicine, swallow the tablet whole without chewing or crushing it. You can take it with or without food, but it's recommended to take it at the same time every day. It's important to continue taking this medicine even when you're not experiencing a gout attack as stopping it may worsen your symptoms.

It is important to inform your doctor about any underlying medical conditions you have or any medications you are currently taking to avoid potential interactions.

Frequently Asked Questions (FAQs)

What is Febubow-40 Tablet used for?

Febubow-40 Tablet is used to prevent and manage gout, a condition characterised by the buildup of uric acid in the body. It helps reduce uric acid levels, preventing the formation of crystals in the joints.

What are the common side effects of Febubow-40 Tablet?

The common side effects of Febubow-40 Tablet may include headache, diarrhoea, nausea, and skin rash.

How long should I take Febubow-40 Tablet?

The duration of treatment with Febubow-40 Tablet varies for each individual and is determined by your doctor. It is usually taken for the long term to prevent gout attacks. Do not stop taking it without your doctor's advice.

Can I take Febubow-40 Tablet if I am pregnant or breastfeeding?

It is important to consult your doctor before taking the Febubow-40 Tablet if you are pregnant or breastfeeding, as it may not be safe for use during these periods.

Can Febubow-40 Tablet be given to children?

The use of the Febubow-40 Tablet in children has not been established yet. Please consult a paediatrician for appropriate treatment options.

Can I drink alcohol while taking Febubow-40 Tablet?

It is recommended to use caution while consuming alcohol with Febubow-40 Tablet, as it may increase the risk of side effects and worsen liver function.

Is it safe to drive or operate machinery while taking Febubow-40 Tablet?

Febubow-40 Tablet may cause dizziness, drowsiness, or blurred vision, which may affect your ability to drive or operate machinery. Use caution and consult your doctor if you experience these side effects.

References

Adenuric 80 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc). (n.d.). https://www.medicines.org.uk/emc/product/487/smpc#gref
Avena-Woods, C. (2010, February 1). Febuxostat (Uloric), A New Treatment Option for Gout. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827920/
Febuxostat: MedlinePlus drug information. (n.d.). https://medlineplus.gov/druginfo/meds/a609020.html#:~:text=Febuxostat%20is%20in%20a%20class,is%20made%20in%20the%20body.
Gerriets, V. (2023, January 7). Febuxostat. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK544239/
Schumacher Jr, H. R., Becker, M. A., Lloyd, E., MacDonald, P. A., & Lademacher, C. (2009). Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology, 48(2), 188-194. https://doi.org/10.1093/rheumatology/kep088
ULORIC (febuxostat) tablet for oral use. (2017, August). FDA.gov. Retrieved August 26, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021856s011lbl.pdf
Becker, M. A., Schumacher Jr, H. R., Wortmann, R. L., MacDonald, P. A., Palo, W. A., Eustace, D., ... & Joseph‐Ridge, N. (2005). Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout. Arthritis & Rheumatism, 52(3), 916-923.
Zeng, X. X., Tang, Y., Hu, K., Zhou, X., Wang, J., Zhu, L., ... & Xu, J. (2018). Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine, 97(13).

Disclaimer

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.